Cargando…
Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
Multimodal treatment is currently the standard of care for locally advanced esophagogastric junction (EGJ) adenocarcinoma due to poor results after surgery alone. Neoadjuvant therapy is intended to shrink the tumor and eliminate potential circulating tumor cells. However, which neoadjuvant treatment...
Autores principales: | Laxague, Francisco, Schlottmann, Francisco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317651/ https://www.ncbi.nlm.nih.gov/pubmed/34367928 http://dx.doi.org/10.5306/wjco.v12.i7.557 |
Ejemplares similares
-
Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction
por: Zheng, Yi-Han, et al.
Publicado: (2022) -
Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis
por: SCHULZE, BJÖRN, et al.
Publicado: (2014) -
Evidence-based approach to the treatment of esophagogastric junction tumors
por: Schlottmann, Francisco, et al.
Publicado: (2022) -
Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management?
por: Samo, Salih, et al.
Publicado: (2019) -
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT
por: Liu, Xiaowen, et al.
Publicado: (2019)